Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06666621 · ClinicalTrials.gov registry record · Phase 4
Endogenous Opioid Response to Injections
A Phase 4 study of Low Back Pain and Zygapophyseal Joint Arthritis, sponsored by Middle Tennessee Research Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT06666621: Recruiting Phase 4 study of Low Back Pain and Zygapophyseal Joint Arthritis, sponsored by Middle Tennessee Research Institute.
NCT06666621 is a Phase 4 study of Low Back Pain and Zygapophyseal Joint Arthritis that is actively recruiting participants, run by Middle Tennessee Research Institute. The registered enrollment target is 33 participants, below the 504-participant average among 122 other Low Back Pain trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06666621, a Phase 4 study of Low Back Pain and Zygapophyseal Joint Arthritis, is actively recruiting participants, sponsored by Middle Tennessee Research Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will study pain relief after spine injections that are used to guide care. Some improvements in pain from a procedure might be from placebo effect rather than the physiological effect of the procedure. The study will use naloxone to reverse the effect of the body's internal placebo system after a spine injection, so the placebo effect and the injection effect can be measured separately. This process may improve the understanding of spine injections and their ability to guide pain care.
Primary Outcome
Endogenous opioid-dependent placebo analgesia is defined as change in analgesia after lumbar medial branch block #1 (measured by numeric pain rating scale) after infusing naloxone
Conditions Studied
Interventions
- DRUG Normal saline infusion
- DRUG Naloxone infusion
Study Locations (1)
Tennessee
- VA Tennessee Valley Healthcare System - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2026-02 |
| Phase | Phase 4 |
What NCT06666621 shows while recruiting
NCT06666621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 504-participant average among 122 other Low Back Pain trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Low Back Pain appearing as the primary indexed condition, and to 2 interventions - of which Normal saline infusion is the first listed.
NCT06666621 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06666621 about?
NCT06666621 is a clinical study titled "Endogenous Opioid Response to Injections". This study will study pain relief after spine injections that are used to guide care. Some improvements in pain from a procedure might be from placebo effect rather than the physiological effect of the procedure. The study will use naloxone to reverse the effect of the body's internal placebo system...
What is the current status of trial NCT06666621?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2024-08-22. Estimated completion is 2026-02.
What conditions does trial NCT06666621 study?
This clinical trial studies the following conditions: Low Back Pain, Zygapophyseal Joint Arthritis.
What interventions are being tested in trial NCT06666621?
The interventions under investigation include: Normal saline infusion (DRUG), Naloxone infusion (DRUG).
Who is sponsoring clinical trial NCT06666621?
This trial is sponsored by Middle Tennessee Research Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06666621 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Back Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06666621's enrollment target sits among peer trials
33 105th of 122 higher than 18 of 122 other Low Back Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Low Back Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Conventional vs Bipolar SIJ RFA for Treatment of Sacroiliac Joint Pain
RECRUITING · Phase 4
-
Trigger Point Injection for Myofascial Pain Syndrome in the Low Back: A Randomized Controlled Trial
RECRUITING · Phase 4
-
Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.
RECRUITING · Phase 4
-
Acute Low Back Pain. Topical Diclofenac and Oral Ibuprofen.
COMPLETED · Phase 4
-
A Comparison of NSAIDs for Acute, Non-radicular Low Back Pain.
COMPLETED · Phase 4
-
Brain Imaging of Lidoderm for Chronic Back Pain
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI